T-1095A and T-1095 are synthetic agents derived from phlorizin, a specific inhibitor of Na+-glucose cotransporters (SGLTs). Unlike phlorizin, T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney. Orally administered T-1095 increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels. Indeed, the postprandial hyperglycemia after a meal load was shown to be suppressed by this compound in streptozotocin (STZ)-induced diabetic rats. With long-term T-1095 treatment, both blood glucose and HbA1c levels were reduced in STZ-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice. Thus, T-1095 may be a useful antidiabetic drug, providing a novel therapeutic approach for diabetes.

中文翻译：

---

T-1095 是一种肾 Na+-葡萄糖协同转运蛋白抑制剂，可能提供一种治疗糖尿病的新方法

T-1095A 和 T-1095 是源自根皮苷的合成药物，根皮苷是 Na+-葡萄糖协同转运蛋白 (SGLT) 的特异性抑制剂。与根皮苷不同，T-1095 通过口服吸收进入循环，代谢为活性形式 T-1095A，并抑制肾脏中 SGLT 的活性。口服 T-1095 可增加糖尿病动物的尿葡萄糖排泄，从而降低血糖水平。事实上，在链脲佐菌素 (STZ) 诱导的糖尿病大鼠中，这种化合物可以抑制进餐后的餐后高血糖。通过长期 T-1095 治疗，STZ 诱导的糖尿病大鼠和黄色 KK 小鼠的血糖和 HbA1c 水平均降低。此外，碳水化合物代谢异常，即高胰岛素血症和高甘油三酯血症得到改善，以及黄色 KK 小鼠微量白蛋白尿的发展。因此，T-1095 可能是一种有用的抗糖尿病药物，为糖尿病提供一种新的治疗方法。